The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of the consortium which compiled it publish the proteomics signatures of major neurodegenerative diseases that they uncovered in a first trawl of the data. Read More
A recent publication in Science Advances has uncovered NMNAT1 as a promising therapeutic target for alcohol-associated liver disease (ALD). Early ALD can be reversible, but prolonged alcohol abuse may lead to progressive steatohepatitis, fibrosis and even cirrhosis or hepatocellular carcinoma. Read More
Ube Corp. and Galts Pharma Co. Ltd., a venture company from Kumamoto University, have signed an agreement giving Galts exclusive worldwide rights to develop, manufacture and market UD-051 (GP-051), a compound discovered through joint research by Ube and Kumamoto University. Read More
GIPR/GLP-1R-targeting agents have demonstrated significant efficacy in appetite suppression and weight reduction; however, their adverse effect profiles and tolerability issues highlight the need for alternative or complementary therapeutic strategies in the management of obesity. Researchers from Juvena Therapeutics Inc. reported on the preclinical profile of JUV-112, discovered using Juvena’s proprietary JuvNET platform. Read More
Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age and characterized by obesity, insulin resistance and renal injury. Read More
Merck Sharp & Dohme LLC has prepared and tested triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of Alzheimer’s disease and neurodegeneration. Read More
Researchers from the University of Copenhagen and the Psychiatric Center Copenhagen have uncovered the cellular and synaptic effects of the drug VU-0364572, a selective modulator of the M1 muscarinic acetylcholine receptor. Read More
Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma. Read More
A recent study published in the journal International Immunopharmacology presents compelling preclinical evidence that NIMA-associated kinase 7 (NEK7), a key regulator of inflammation, may play a pivotal role in the pathology of depression. Read More
2A Biosciences Inc. has described phenethylamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders. Read More
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, with few successful treatment options. HCC development is associated with established risk factors, including metabolic dysregulation, repeated insults by hepatotoxins or infection by hepatotropic viruses. Read More
AGC Inc. has synthesized compounds acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer. Read More
Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders. Read More
Multiple sclerosis (MS) is a degenerative and inflammatory condition of the central nervous system (CNS) that impacts more than 2.5 million individuals globally. Interleukin-33 (IL-33) is an immunoregulatory cytokine that has shown a mild inhibitory effect on experimental autoimmune encephalomyelitis (EAE), which serves as a mouse model for MS. However, its clinical application is limited by unfavorable pharmacokinetics and associated toxicity. Read More
Obesity and diabetes are known risk factors for sarcopenia. Insulin resistance that occurs during type 2 diabetes promotes impaired synthesis of muscle protein and muscle breakdown. Juvena Therapeutics Inc. has presented data at ENDO 2025 conference for JUV-161, a novel secreted protein that induces insulin sensitization, regarding its impact on blood glucose and muscle in mice with type 2 diabetes (db/db mice). Read More
